Genscript Biotech climbs as cancer drug CARVYKTI generated $597 mln sales

Genscript Biotech

15/04/2026 06:59

** Shares of Genscript Biotech Corporation 1548.HK climb 4.5% to HK$13.27, on track for the biggest one-day pct gain since April 1

** Stock hit the highest level since April 9 in the second session of rise

** Genscript said its associate Legend Biotech Corp LEGN.O announced that blood cancer drug CARVYKTI generated about $597 mln in net trade sales during the quarter ended in March 2026

** YTD, Genscript Hong Kong stock up 6.2%, Hang Seng Biotech Index .HSBIO up 11.9%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))